

## **CVs of the candidates for the election to the Supervisory Board 2025**

### **Dr Karl Benedikt Biesinger**

*Lawyer and partner at biesinger diener Rechtsanwalts-gesellschaft mbH, Heidelberg*

Dr Karl Benedikt Biesinger is an attorney and partner at biesinger diener Rechtsanwalts-gesellschaft mbH in Heidelberg. He completed his law studies at the Eberhard Karls University of Tübingen and the Albert Ludwig University of Freiburg, Germany. He received his doctorate from the University of Tübingen, Germany. Dr Biesinger worked as a research assistant at the Max Planck Institute for Foreign and International Criminal Law in Freiburg and at the Chair of Civil and Commercial Law at the Eberhard Karls University of Tübingen. Dr Biesinger is Chairman of the Supervisory Board of SNP Schneider-Neureither & Partner SE (Data Transformation) and founder and managing director of Oorcca GmbH (ERP software).

### **Dr Klaus Schollmeier**

*Advisor to the Pharma and Biotech industry and business angel*

Dr. Klaus Schollmeier is a consultant for pharmaceutical and biotech companies. Dr. Schollmeier holds a doctorate in biology from the University of Düsseldorf, Germany, and has been an Associate Professor of Research at Boston University Medical School, Massachusetts, USA, since 1991.

Dr. Schollmeier can look back on many years of experience as a board member of various biotech and pharmaceutical companies, including SuppreMol, Munich, Germany, Santhera, Basel, Switzerland, and Graffinity Pharmaceuticals AG, Heidelberg, Germany. He previously held various positions at ING-BHF Bank, BASF, Knoll and Abbott. He is also Chairman of the Supervisory Board of Tacalyx AG and a member of the Supervisory Boards of Eternygen GmbH, CureVac, Novaliq, Anergis Pharma, Affiris Pharma and Modra Pharmaceuticals and act as business angel for start-up companies in Europe.

### **Dr. Georg F. Baur (Deputy Chairman)**

*Entrepreneur, Vice chairman of the Supervisory Board of Heidelberg Pharma AG*

Dr Georg F. Baur was re-elected to the Supervisory Board on 22 July 2020 and is its current Deputy Chairman. Dr Baur works as an entrepreneur in the areas of private investments and asset management. Before he was Managing Partner of Lehndorff Vermögensverwaltungs GmbH and held various positions at JP Morgan, ultimately as Managing Director and Treasurer of the bank in London. He holds a PhD in economics from the University of St. Gallen, Switzerland.

### **Dr. Mathias Hothum (Deputy Chairman)**

*Managing Director of dievini Verwaltungs GmbH, which is the General Partner of dievini Hopp BioTech holding GmbH & Co. KG, Walldorf; Vice chairman of the Supervisory Board of Heidelberg Pharma AG*

Dr Mathias Hothum was re-elected as a member of the Supervisory Board at the Annual General Meeting on 22 July 2020 and is its current Deputy Chairman. Dr Hothum serves as Managing Director of dievini Verwaltungs GmbH. dievini manages the biotech investments of

SAP co-founder Dietmar Hopp and his family. Dr Hothum has been the owner and managing director of HMM Consulting in Walldorf since 1992. He has almost 30 years of experience as a consultant for companies in the healthcare sector. Dr Hothum studied economics at the University of Mannheim and received his doctorate from the University of Magdeburg, Germany.

**Dr. Birgit Kudlek**

*Independent manager in the pharmaceutical industry*

Dr Birgit Kudlek was re-elected as member of the Supervisory Board at the Annual General Meeting on 22 July 2020. She is an independent manager in the pharmaceutical industry. Prior to that, Dr. Kudlek held management positions in pharmaceutical companies for many years, including Mundipharma International, AENOVA Holding GmbH, Sandoz International and LTS Lohmann Therapy Systems. Birgit Kudlek studied Pharmaceutical Science as well as Economics and holds a PhD in Pharmaceutical Technology from the Technical University of Braunschweig, Germany.

**Dr Dongzhou Jeffery Liu**

*CSO and President of Huadong Global Development, Huadong Medicine Co., Ltd., Hangzhou, China*

Dr. Liu was elected by the Annual General Meeting on 28 June 2022. Since 2020, Dr. Liu is Chief Scientific Officer (CSO) at Huadong Medicine and President of Huadong Global Development in Hangzhou, China. Prior to that, he served as President at Raynovent Biotechnology Co., Ltd, Guangzhou, China. Before that Dr. Liu held various positions in Pharma companies, such as GlaxoSmithKline (USA), Wyeth (USA, now Pfizer) or Forest Labs (USA, now Allergan). His more than 25 years of industry experience including clinical and preclinical research & development of medicinal products. He contributed to several globally launched products. He has more than 100 publications and applied 80+ patents with 20+ granted. He is the lecture professors of Zhejiang University, and Hefei Institute of CAS, China. He completed his post-doctoral fellowships at University of North Carolina at Chapel Hill & University of Louisville at Kentucky, USA. He obtained a PhD in Immunology/Biochemistry from Nankai University, Tianjin, China, an EMBA from the State University of New York at Stony Brook, USA, a Master of Science in computer sciences from New York Long Island University, New York, USA, and a Bachelor of Science in Chemistry, Nankai University.

**Dr Yan Xia**

*Director of ADC Research Center, Huadong Medicine Co., Ltd, Hangzhou, China*

Dr Xia was elected by the Annual General Meeting on 25 May 2023. Has been the Director of ADC Research Center at Huadong Medicine in Hangzhou, China since 2022. He leads the early research and development of the ADC pipeline and develops Huadong Medicine's R&D strategy. Furthermore, he led the preclinical biology team and conducted several projects, including a collaborative drug discovery project for innovative cancer therapeutics using AI and a preclinical co-discovery and development project. In addition, Dr. Xia has been responsible for due diligence processes for in-licensing or strategic acquisitions, R&D strategies, and pipeline strategies. Dr. Xia holds a Ph.D. in chemical and physical biology from Vanderbilt University, Nashville, Tennessee, USA, and a B.Sc. in biological sciences from Nanyang Technological University, Singapore.